Cancer Research and Treatment

Original Articles

Head and Neck cancer

Long-term Survivorship and Non-cancer Competing Mortality in Head and Neck Cancer: A Nationwide Population-Based Study in South Korea: Yuh-Seog Jung, Dahhay Lee, Kyu-Won Jung, Hyunsoon Cho; Cancer Res Treat. 2023;55(1):50-60. Published online March 4, 2022; DOI: https://doi.org/10.4143/crt.2021.1086

Abstract PDF Supplementary Material PubReader ePub

Purpose
As the survival of head and neck cancer (HNC) improves, survivors increasingly confront non-cancer–related deaths. This nationwide population-based study aimed to investigate non-cancer–related deaths in HNC survivors.
Materials and Methods
Data from the Korean Central Cancer Registry were obtained to characterize causes of death, mortality patterns, and survival in patients with HNC between 2006 and 2016 (n=40,890). Non-cancer-related mortality relative to the general population was evaluated using standardized mortality ratios (SMRs). The 5- and 10-year cause-specific competing risks probabilities of death (cumulative incidence function, CIF) and subdistribution hazards ratios (sHR) from the Fine-Gray models were estimated.
Results
Comorbidity-related mortality was frequent in older patients, whereas suicide was predominant in younger patients. The risk of suicide was greater in patients with HNC than in the general population (SMR, 3.1; 95% confidence interval [CI], 2.7 to 3.5). The probability of HNC deaths reached a plateau at 5 years (5-year CIF, 33.9%; 10-year CIF, 39.5%), whereas the probability of non-HNC deaths showed a long-term linear increase (5-year, CIF 5.6%; 10-year CIF, 11.9%). Patients who were male (sHR, 1.56; 95% CI, 1.41 to 1.72), diagnosed with early-stage HNC (localized vs. distant: sHR, 1.86; 95% CI, 1.58 to 2.21) and older age (65-74 vs. 0-44: sHR, 6.20; 95% CI, 4.92 to 7.82; ≥ 75 vs. 0-44: sHR, 9.81; 95% CI, 7.76 to 12.39) had an increased risk of non-cancer mortality.
Conclusion
Non-HNC–related deaths continue increasing. HNC survivors are at increased risk of suicide in the younger and comorbidity-related death in the older. Better population-specific surveillance awareness and survivorship plans for HNC survivors are warranted.

Citations

Citations to this article as recorded by

Time‐varying association of second primary malignancy and long‐term survival outcomes in patients with head and neck cancer
Xiaoke Zhu, Yu Heng, Jian Zhou, Hanqing Lin, Liang Zhou, Ming Zhang, Pengyu Cao, Lei Tao
International Journal of Cancer.2023; 153(1): 94. CrossRef

4,993 View
152 Download
1 Web of Science
1 Crossref

Effect of National Oral Health Screening Program on the Risk of Head and Neck Cancer: A Korean National Population-Based Study: Chan Woo Wee, Hyo-Jung Lee, Jae-Ryun Lee, Hyejin Lee, Min-Jeong Kwoen, Woo-Jin Jeong, Keun-Yong Eom; Cancer Res Treat. 2022;54(3):709-718. Published online October 22, 2021; DOI: https://doi.org/10.4143/crt.2021.834

Abstract PDF Supplementary Material PubReader ePub

Purpose
Poor oral health is associated with head and neck cancer (HNC). We evaluated whether a national oral health screening program (OHSP) could reduce the risk of HNC.
Materials and Methods
Data from 408,247 healthy individuals aged ≥ 40 years from the National Health Insurance System-National Health Screening program during 2003 and 2004 in Korea were analyzed. The risk of HNC was compared between subjects who underwent OHSP (HEALS-Dental+, n=165,292) and routine health check-ups only (HEALS-Dental‒, n=242,955). The impact of individual oral health-related factors on HNC risk was evaluated in HEALS-Dental+.
Results
A total of 1,650 HNC cases were diagnosed. The 10-year HNC-free rate was 99.684% with a median follow-up of 11 years. The risk of all HNC (hazard ratio [HR], 1.16; 95% confidence interval [CI], 1.03 to 1.29; p=0.011) and oropharyngeal cancer (HR, 1.48; 95% CI, 1.13 to 1.94; p=0.005) was significantly higher in HEALS-Dental‒ than in HEALS-Dental+. In HEALS-Dental+, oral cavity cancer was marginally reduced (p=0.085), and missing teeth was a significant factor for HNC (HR, 1.24; 95% CI, 1.02 to 1.50; p=0.032). Toothbrushing was a significant factor in univariate analysis (p=0.028), but not in multivariate analysis (p=0.877).
Conclusion
The National OHSP significantly reduced the long-term HNC risk, particularly the incidence of oropharyngeal cancer. Routine OHSP should be considered at the population level.

Citations

Citations to this article as recorded by

Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo
Takumi Sato, Yasumasa Kakei, Takumi Hasegawa, Masahiko Kashin, Shun Teraoka, Akinobu Yamaguchi, Ryohei Sasaki, Masaya Akashi
Cancers.2023; 15(23): 5697. CrossRef

6,207 View
138 Download
1 Web of Science
1 Crossref

Radiation-Induced Ocular Surface Disorders and Retinopathy: Ocular Structures and Radiation Dose-Volume Effect: Ozlem Ozkaya Akagunduz, Suzan Guven Yilmaz, Emin Tavlayan, Mine Esen Baris, Filiz Afrashi, Mustafa Esassolak; Cancer Res Treat. 2022;54(2):417-423. Published online June 24, 2021; DOI: https://doi.org/10.4143/crt.2021.575

Abstract PDF PubReader ePub

Purpose
This study aimed to evaluate the radiation-induced adverse effects on ocular structures in head and neck cancer patients and investigate the radiation dose-volume effects on the cornea, lacrimal gland, retina, optic nerve and chiasm.
Materials and Methods
A total of 38 eyes of 19 patients were included in this prospective, cohort study. All patients underwent complete ophthalmological examination in addition to contrast sensitivity, visual field and visual evoked potentials (VEP) tests. Ophthalmological examinations and psychophysical tests were performed in 6th, 12th, 18th, 24th months and in the last visit. The relationship between the ophthalmologic findings, and the radiation doses below and above the cut-off values was evaluated.
Results
Contrast sensitivity decrease and visual field deterioration were observed in 42% of the patients in the last visit (median 26 months) whereas a prolonged latency and decreased amplitude of P100 wave in VEP was observed in 58% and 33% of the eyes, respectively at 24th month. Totally 16 patients (84.2%) developed dry eye disease and eight of them received radiotherapy below tolerance doses and had mild to moderate dry eye findings. Radiation-induced retinopathy was observed in three of the eyes in eight patients who received radiation above tolerance dose.
Conclusion
Head and neck cancers treated with radiotherapy, resulted in various ophthalmic complications. All patients who are treating with radiotherapy should be evaluated by an ophthalmologist in terms of anterior and posterior segment damage, even if the radiation dose is below the tolerance limit.

Citations

Citations to this article as recorded by

Neurological complications of modern radiotherapy for head and neck cancer
James C.H. Chow, Jason C.S. Ho, Ka Man Cheung, David Johnson, Bonaventure Y.M. Ip, Jonathan J. Beitler, Primož Strojan, Antti A. Mäkitie, Avraham Eisbruch, Sweet Ping Ng, Sandra Nuyts, William M. Mendenhall, Silvia Babighian, Alfio Ferlito
Radiotherapy and Oncology.2024; 194: 110200. CrossRef
Efficacy of Intravitreal Injections Anti-Vascular Endothelial Growth Factor Treatment for Radiation Retinopathy: A Systematic Review and Meta-analysis
Jiayuan Zhuang, Yang Yang, Yuexia Liao, Chenghao Li, Wen-an Wang, Xiangxia Luo, Heng Zhou
American Journal of Ophthalmology.2024; 263: 141. CrossRef
Personalized treatment for patients with lacrimal sac squamous cell carcinoma
Jie Wang, Qi Zhang, Xiuqian Yi, Tianci Tang, Tian Wang, Xinmao Song
Canadian Journal of Ophthalmology.2024; 59(6): e768. CrossRef
Biomaterials-mediated radiation-induced diseases treatment and radiation protection
Jianping Man, Yanhua Shen, Yujie Song, Kai Yang, Pei Pei, Lin Hu
Journal of Controlled Release.2024; 370: 318. CrossRef
Retinopatía por radiación vs. síndrome isquémico ocular: ¿cómo llegar al diagnóstico?
A. Aramburu-González, J. Zarrabeitia Carrandi, C.B. Robles Elejalde, A. Quilez Larragan
Archivos de la Sociedad Española de Oftalmología.2024; 99(8): 352. CrossRef
Orbital cavernous venous malformation shrinkage during fractionated stereotactic radiotherapy contributing to the development of radiation retinopathy
Laura Hughes, Amy C Cohn, Neda Haghighi, Alan A McNab
European Journal of Ophthalmology.2024; 34(5): NP53. CrossRef
Radiation retinopathy vs. ocular ischemic syndrome: how to reach the diagnosis?
A. Aramburu-González, J. Zarrabeitia Carrandi, C.B. Robles Elejalde, A. Quilez Larragan
Archivos de la Sociedad Española de Oftalmología (English Edition).2024; 99(8): 352. CrossRef
Ocular surface changes in patients who have undergone head and neck radiation therapy
H Sujithra, Kannisha N Shah, R Anoop, Pushpaja K Ullattil, Gopal S Pillai, Greeshma C Ravindran, Jayesh Vazirani
Indian Journal of Ophthalmology.2024;[Epub] CrossRef
New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?
Giuseppa Scandurra, Valentina Lombardo, Giuseppe Scibilia, Daniela Sambataro, Vittorio Gebbia, Paolo Scollo, Basilio Pecorino, Maria Rosaria Valerio
Cancers.2024; 16(13): 2466. CrossRef
Radiation-Induced Retinopathy and Optic Neuropathy after Radiation Therapy for Brain, Head, and Neck Tumors: A Systematic Review
Buket Kinaci-Tas, Tanja Alderliesten, Frank D. Verbraak, Coen R. N. Rasch
Cancers.2023; 15(7): 1999. CrossRef
Radiation Retinopathy
Kaylie Chen, Andrew W. Browne
Current Ophthalmology Reports.2023; 11(3): 49. CrossRef
Case Report: Optical coherence tomography angiography findings in radiation retinopathy
Wafa Ammari, Asma Zaghdoudi, Olfa Berriche, Riadh Messaoud
F1000Research.2023; 11: 968. CrossRef
Case Report: Optical coherence tomography angiography findings in radiation retinopathy
Wafa Ammari, Asma Zaghdoudi, Olfa Berriche, Riadh Messaoud
F1000Research.2023; 11: 968. CrossRef
Efficacy and Safety of Radiotherapy Combined with Pyrotinib in the Treatment of HER2-Positive Breast Cancer with Brain Metastases
Jie Huang, Wenqiang Zhu, Qiangzhi Duan, Chaomang Zhu, Xueling Shi, Hongyu Zhao, Peng Cai, Duojie Li
Breast Cancer: Targets and Therapy.2023; Volume 15: 841. CrossRef
Comparable meibomian gland changes in patients with and without ocular graft-versus-host disease after hematopoietic stem cell transplantation
Wenxin Zhao, Jing Yang, Yinglin Liao, Hubert Yuenhei Lao, Quanbin Huang, Ling Jin, Jing Sun, Fen Huang, Lingyi Liang
The Ocular Surface.2022; 25: 1. CrossRef
Case Report: Optical coherence tomography angiography findings in radiation retinopathy
Wafa Ammari, Asma Zaghdoudi, Olfa Berriche, Riadh Messaoud
F1000Research.2022; 11: 968. CrossRef
Corneal Epithelial Stem Cells–Physiology, Pathophysiology and Therapeutic Options
Yue Ruan, Subao Jiang, Aytan Musayeva, Norbert Pfeiffer, Adrian Gericke
Cells.2021; 10(9): 2302. CrossRef

7,299 View
384 Download
11 Web of Science
17 Crossref

Head and Neck Cancer

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12: Yun-Gyoo Lee, Hyun Chang, Bhumsuk Keam, Sang Hoon Chun, Jihyun Park, Keon Uk Park, Seong Hoon Shin, Ho Jung An, Kyoung Eun Lee, Keun-Wook Lee, Hye Ryun Kim, Sung-Bae Kim, Myung-Ju Ahn, In Gyu Hwang; Cancer Res Treat. 2021;53(3):671-677. Published online December 7, 2020; DOI: https://doi.org/10.4143/crt.2020.824

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis.
Materials and Methods
We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes.
Results
The patients received anti–programmed cell death protein-1 (PD-1) (n=73, 58%), anti–programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti–PD-1/PD-L1 and anti–cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival.
Conclusion
ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI.

Citations

Citations to this article as recorded by

Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun
Oral Oncology.2024; 151: 106739. CrossRef
Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
Lei Liu, Qiang Liu
Scientific Reports.2024;[Epub] CrossRef
Inflammatory markers as prognostic markers in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Quan Wang, Xiangzhi Yin, Shengxia Wang, Haijun Lu
Frontiers in Oncology.2024;[Epub] CrossRef
Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma
Dong Hyun Kim, Seo Yoon Jang, Bhumsuk Keam
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2024;[Epub] CrossRef
Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
Piero Giuseppe Meliante, Federica Zoccali, Marco de Vincentiis, Massimo Ralli, Carla Petrella, Marco Fiore, Antonio Minni, Christian Barbato
Diagnostics.2023; 13(5): 862. CrossRef
Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols
Catherine T. Haring, Lulia A. Kana, Sarah M. Dermody, Collin Brummel, Jonathan B. McHugh, Keith A. Casper, Steven B. Chinn, Kelly M. Malloy, Michelle Mierzwa, Mark E. P. Prince, Andrew J. Rosko, Jennifer Shah, Chaz L. Stucken, Andrew G. Shuman, J. Chad Br
Cancer.2023; 129(18): 2817. CrossRef
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review
Camil Ciprian Mireștean, Mihai Cosmin Stan, Michael Schenker, Constantin Volovăț, Simona Ruxandra Volovăț, Dragoș Teodor Petru Iancu, Roxana Irina Iancu, Florinel Bădulescu
Diagnostics.2023; 13(16): 2620. CrossRef
Integrating Cutting-Edge Methods to Oral Cancer Screening, Analysis, and Prognosis
Sagar Dholariya, Ragini D. Singh, Amit Sonagra, Dharamveer Yadav, Bhairavi N. Vajaria, Deepak Parchwani
Critical Reviews™ in Oncogenesis.2023; 28(2): 11. CrossRef
Neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Tibera K. Rugambwa, Omar Abdihamid, Xiangyang Zhang, Yinghui Peng, Changjing Cai, Hong Shen, Shan Zeng, Wei Qiu
Frontiers in Oncology.2023;[Epub] CrossRef
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Surviva
Khalil Choucair, Caroline Nebhan, Alessio Cortellini, Stijn Hentzen, Yinghong Wang, Cynthia Liu, Raffaele Giusti, Marco Filetti, Paolo Antonio Ascierto, Vito Vanella, Domenico Galetta, Annamaria Catino, Nour Al-Bzour, Azhar Saeed, Ludimila Cavalcante, Pam
Cancers.2023; 15(20): 5052. CrossRef
A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors
Dengxiong Kang, Siping Liu, Xin Yuan, Shenxiang Liu, Zhengrong Zhang, Zhilian He, Xudong Yin, Haiyan Mao
Journal of Cancer Research and Clinical Oncology.2023; 149(20): 18215. CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients
Jun-Liang Li, Tsai-Ling Hsieh, Ming-Che Ou, Frank Cheau-Feng Lin, Stella Chin-Shaw Tsai
Oral Oncology.2022; 126: 105729. CrossRef
Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis
Yukinori Takenaka, Ryohei Oya, Norihiko Takemoto, Hidenori Inohara
Head & Neck.2022; 44(5): 1237. CrossRef
Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
Maria A. Lopez-Olivo, Valeria Valerio, Aliza R. Karpes Matusevich, Marianela Brizio, Michelle Kwok, Yimin Geng, Maria E. Suarez-Almazor, Ines Colmegna
Vaccines.2022; 10(8): 1195. CrossRef
Identification of Immune-Related LncRNA Pairs for Predicting Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma
Xueying Wang, Kui Cao, Erliang Guo, Xionghui Mao, Lunhua Guo, Cong Zhang, Junnan Guo, Gang Wang, Xianguang Yang, Ji Sun, Susheng Miao
Frontiers in Immunology.2021;[Epub] CrossRef
Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma
Xing-xing Huo, Shu-jie Wang, Hang Song, Ming-de Li, Hua Yu, Meng Wang, Hong-xiao Gong, Xiao-ting Qiu, Yong-fu Zhu, Jian-ye Zhang
Frontiers in Pharmacology.2021;[Epub] CrossRef

7,190 View
225 Download
15 Web of Science
16 Crossref

Prediction of Lymph Node Metastasis by Tumor Dimension Versus Tumor Biological Properties in Head and Neck Squamous Cell Carcinomas: Jeon Yeob Jang, Min Ji Kim, Gwanghui Ryu, Nayeon Choi, Young-Hyeh Ko, Han-Sin Jeong; Cancer Res Treat. 2016;48(1):54-62. Published online March 6, 2015; DOI: https://doi.org/10.4143/crt.2014.332

Abstract PDF PubReader ePub

Purpose
Lymph node metastasis (LNM) is a strong prognostic factor in many solid cancers, including head and neck squamous cell carcinomas (HNSCC), and LNM can be dependent upon primary tumor biology, as well as tumor dimension. Here, we investigate the relative risk of LNM in accordance to tumor dimension and biology in HNSCC subsites.
Materials and Methods
Medical data of 295 HNSCC patients who had undergone the initial curative surgery (oral tongue 174, oropharynx 75, hypopharynx 46) were analyzed to identify the significant predictive factor for LNM. Tumor volume and thickness were set as tumor dimensional variables, and biological variables included lymphovascular, perineural invasion, and tumor differentiation. Statistical analyses were conducted to assess the predictability of LNM from variables, and subgroup analyses according to the tumor subsites. In addition, we evaluated the impacts of tumor dimension and biological variables on the treatment outcomes and survival in HNSCC subsites.
Results
The overall tumor dimension and biological variables had a similar impact on the prediction of LNM in HNSCC (area under curve, 0.7682 and 0.7717). The prediction sensitivity of LNM in oral tongue cancer was mainly dependent on tumor dimension, while LNM in oro- and hypo-pharynx cancers was more influenced by biological factors. Survival analyses also confirmed that biological factor was more powerful in estimating disease-free survival of hypopharyngeal cancer patients, while tumor dimension was more significant in that of oral cancer patients.
Conclusion
Tumor dimension and biology have a significant, tumor subsite-dependent impact on the occurrence of LNM and disease-free survival in HNSCC.

Citations

Citations to this article as recorded by

Extra-Capsular Spread of Lymph Node Metastasis in Oral, Oropharyngeal and Hypopharyngeal Cancer: A Comparative Subsite Analysis
Yung Jee Kang, Goeun Park, Sung Yool Park, Taehwan Kim, Eunhye Kim, Yujin Heo, Changhee Lee, Han-Sin Jeong
Cancers.2024; 16(3): 659. CrossRef
The Prognostic Role of Perineural Invasion for Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Zhuo-Ying Tao, Guang Chu, Yu-Xiong Su
Cancers.2024; 16(14): 2514. CrossRef
A preoperative nomogram model for the prediction of lymph node metastasis in buccal mucosa cancer
Qian Chen, Rui Wei, Shan Li
Cancer Medicine.2023; 12(13): 14120. CrossRef
The Prognostic Prediction Value of Positive Lymph Nodes Numbers for the Hypopharyngeal Squamous Cell Carcinoma
Wendu Pang, Yaxin Luo, Junhong Li, Danni Cheng, Yufang Rao, Minzi Mao, Ke Qiu, Yijun Dong, Jun Liu, Jian Zou, Haiyang Wang, Fei Chen
Frontiers in Medicine.2022;[Epub] CrossRef
Crosstalk between head and neck cancer cells and lymphatic endothelial cells promotes tumor metastasis via CXCL5‐CXCR2 signaling
Bok‐Soon Lee, Jeon Yeob Jang, Chorong Seo, Chul‐Ho Kim
The FASEB Journal.2021;[Epub] CrossRef
A nomogram for predicting occult lymph node metastasis in early hypopharyngeal cancer with cN0
Xiaohui Yuan, Chi-Yao Hsueh, Ming Zhang, Lei Tao, Liang Zhou
European Archives of Oto-Rhino-Laryngology.2021; 278(9): 3515. CrossRef
Individualized elective irradiation of the clinically node‐negative neck in definitive radiotherapy for head and neck squamous cell carcinoma
Jia Kou, Li Lin, Cheng‐Yang Jiao, Meng‐Qiu Tian, Guan‐Qun Zhou, Xue Jiang, Jun Ma, Zhen‐Yu Qi, Yao Lu, Ying Sun
Cancer Communications.2021; 41(4): 303. CrossRef
The prognostic value of tumor depth for cervical lymph node metastasis in hypopharyngeal and supraglottic carcinomas
Lu‐Lu Ye, Jia Rao, Xing‐Wen Fan, Fang‐Fang Kong, Chao‐Su Hu, Hong‐Mei Ying
Head & Neck.2019; 41(7): 2116. CrossRef
Patients with unilateral squamous cell carcinoma of the tongue and ipsilateral lymph node metastasis do not profit from bilateral neck dissection
Christoph Klingelhöffer, Andreas Gründlinger, Gerrit Spanier, Stephan Schreml, Maximilian Gottsauner, Steffen Mueller, Johannes K. Meier, Torsten E. Reichert, Tobias Ettl
Oral and Maxillofacial Surgery.2018; 22(2): 185. CrossRef
Comparison of tumor volume, thickness, and T classification as predictors of outcomes in surgically treated squamous cell carcinoma of the oral tongue
Manish Mair, Deepa Nair, Sudhir Nair, Akshat Malik, Aseem Mishra, Sadhana Kannan, Saurabh Bobdey, Hitesh Singhvi, Pankaj Chaturvedi
Head & Neck.2018; 40(8): 1667. CrossRef
pN status predicts outcomes in surgically treated pT1–pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study
Xu Qian, Branko Sinikovic, Frank Schreiber, Sebastian Ochsenreither, Konrad Klinghammer, Barbara Wollenberg, Andreas M. Kaufmann, Andreas E. Albers
European Archives of Oto-Rhino-Laryngology.2018; 275(11): 2787. CrossRef
Predictive markers for delayed lymph node metastases and survival in early-stage oral squamous cell carcinoma
Ivica Luksic, Petar Suton
Head & Neck.2017; 39(4): 694. CrossRef
Measurement of tumor volume is not superior to diameter for prediction of lymph node metastasis in early gastric cancer with minute submucosal invasion
Jeung Hui Pyo, Sun-Ju Byeon, Hyuk Lee, Yang Won Min, Byung-Hoon Min, Jun Haeng Lee, Kyoung-Mee Kim, Hyeon Seon Ahn, Kyunga Kim, Yoon-Ho Choi, Jae J. Kim
Oncotarget.2017; 8(69): 113758. CrossRef
Mechanisms of Lymph Node Metastasis in Head and Neck Cancer
Jeon Yeob Jang
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2016; 59(4): 259. CrossRef
Analysis of angiogenic markers in oral squamous cell carcinoma-gene and protein expression
Susanne Jung, Sonja Sielker, Nikolai Purcz, Christoph Sproll, Yahya Acil, Johannes Kleinheinz
Head & Face Medicine.2015;[Epub] CrossRef

13,335 View
130 Download
15 Web of Science
15 Crossref

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma: Myoung Hee Kang, Jung Hun Kang, Haa-Na Song, Bae Kwon Jeong, Gyu Young Chai, Kimun Kang, Seung Hoon Woo, Jung Je Park, Jin Pyeong Kim; Cancer Res Treat. 2015;47(3):441-447. Published online December 2, 2014; DOI: https://doi.org/10.4143/crt.2013.219

Abstract PDF PubReader ePub

Purpose
Concurrent chemoradiation (CRT) with 3-weekly doses of cisplatin is a standard treatment for loco-regionally advanced head and neck squamous cell carcinoma (HNSCC). However, treatment with 3-weekly doses of cisplatin is often associated with several adverse events. Therefore, we conducted this retrospective analysis to determine the efficacy and tolerance of CRT with a low weekly dose of cisplatin in stage IV HNSCC patients.
Materials and Methods
Medical records of patients who were diagnosed with stage IV HNSCC and received concurrent CRT were analyzed. All patients were treated weekly with cisplatin at 20-30 mg/m2 until radiotherapy was completed.
Results
A total of 35 patients were reviewed. Median follow up was 10.7 months (range, 1.7 to 90.5 months), the median radiation dose was 7,040 cGy, and the median dose of cisplatin received was 157 mg/m2. Eleven patients received docetaxel combination chemotherapy. Overall, 25 patients (71.4%) achieved complete response (CR), eight (22.9%) showed partial response. The median overall survival was 42.7 months, the 3-year survival rate was 51.2% and the 3 year disease-free survival rate was 72.8%. Overall survival was improved in patients who achieved CR relative to others (59.7 months vs. 13.4 months; p=0.008). There were significant differences in survival between patients who received docetaxel combination and cisplatin alone (51.8 months vs. 7.9 months; p=0.009). Grade 3-4 adverse events included stomatitis (82.9%), dermatitis (22.9%), infection (11.4%), dysphagia (8.6%), and neutropenia (5.7%).
Conclusion
CRT with low dose weekly cisplatin is likely effective and tolerable, even in patients with locally advanced-stage IV HNSCC.

Citations

Citations to this article as recorded by

Transcriptomic analysis reveals differential adaptation of colorectal cancer cells to low and acute doses of cisplatin
Heena Saini, Rakshita Dave, Subhashree Chatterjee, Ayushi Mandloi, Harshita Sharma, Ankita Daiya, Sudeshna Mukherjee, Rajdeep Chowdhury, Shibasish Chowdhury
Gene.2023; 864: 147304. CrossRef
A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck
Shruthi Venkateshulu, Kiran Kumar BR
Cureus.2021;[Epub] CrossRef
Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma
Adity Chakraborty, Abhinandan Bhattacharjee, Amlan Jyoti Nath, Shibashis Deb, Aakanksha Rathor
The Egyptian Journal of Otolaryngology.2021;[Epub] CrossRef
Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury
Kranti A. Mapuskar, Emily J. Steinbach, Amira Zaher, Dennis P. Riley, Robert A. Beardsley, Jeffery L. Keene, Jon T. Holmlund, Carryn M. Anderson, Diana Zepeda-Orozco, John M. Buatti, Douglas R. Spitz, Bryan G. Allen
Antioxidants.2021; 10(9): 1329. CrossRef
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
BMC Cancer.2020;[Epub] CrossRef
Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma
Minsu Kwon, Dae Hwan Kim, Ki Ju Cho, Youngchul Kim, Jin Pyeong Kim, Bae Kwon Jeong, Jong Sil Lee, Ji-Hyun Seo, Jung Je Park
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2019; 62(12): 712. CrossRef
Topical issues of chemoradiotherapy for oropharyngeal squamous cell carcinoma: the efficiency and toxicity of chemotherapy regimens with the goal of radiomodification
A. I. Stukan, R. A. Murashko, V. N. Bodnya, Yu. M. Makarova, I. N. Vasilenko
Onkologiya. Zhurnal imeni P.A.Gertsena.2018; 7(3): 61. CrossRef
Persistent Head and Neck Cancer Following First-Line Treatment
Teresa Bernadette Steinbichler, Madeleine Lichtenecker, Maria Anegg, Daniel Dejaco, Barbara Kofler, Volker Hans Schartinger, Maria-Therese Kasseroler, Britta Forthuber, Andrea Posch, Herbert Riechelmann
Cancers.2018; 10(11): 421. CrossRef
Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?
Stuart E. Samuels, Avraham Eisbruch, Jonathan J. Beitler, June Corry, Carol R. Bradford, Nabil F. Saba, Michiel W. M. van den Brekel, Robert Smee, Primož Strojan, Carlos Suárez, William M. Mendenhall, Robert P. Takes, Juan P. Rodrigo, Missak Haigentz, Ale
European Archives of Oto-Rhino-Laryngology.2016; 273(10): 2877. CrossRef

14,170 View
96 Download
10 Web of Science
9 Crossref

Analysis of the Prognostic Factors for Distant Metastasis after Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Head and Neck Cancer: Dong Hyun Kim, Won Taek Kim, Joo Hye Lee, Yong Kan Ki, Ji Ho Nam, Byung Joo Lee, Jin Choon Lee, Young Jin Choi, Young Mi Seol, Dong Won Kim; Cancer Res Treat. 2015;47(1):46-54. Published online August 25, 2014; DOI: https://doi.org/10.4143/crt.2013.212

Abstract PDF PubReader ePub

Purpose
The aim of this study is to identify the prognostic factors of distant metastasis (DM) after induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer (HNC). Materials and Methods A total of 321 patients with HNC who underwent IC followed by CRT treated between January 2005 and December 2010 were analyzed retrospectively. IC consisted of three courses of docetaxel (70 mg/m2) and cisplatin (75 mg/m2) every three weeks, followed by radiotherapy of 66-70 Gy/2 Gy per fraction/5 fractions per week concurrent with weekly cisplatin (40 mg/m2). Tumor/nodal stage, primary site, tumor differentiation, lower neck node involvement (level IV, VB, and supraclavicular regions), number of concurrent chemotherapy cycles, overall duration of radiotherapy, and response to IC were assessed as potential prognostic factors influencing DM and survival outcome. Results The five-year loco-regional recurrence and DM rates were 23.6% and 18.2%. N stage, overall duration of radiotherapy, lower neck node involvement, and response to IC were significant factors for DM. With a median follow-up period of 52 months (range, 4 to 83 months), the 5-year progression-free, DM-free, and overall survival rates were 41.2%, 50.7%, and 55.1%, respectively. Lower neck node involvement (p=0.008) and poor response to IC (p < 0.001) showed an association with significantly inferior DM-free survival. Conclusion Even with the addition of IC, the DM rate and survival outcome were poor when metastatic lower neck lymph nodes were present or when patients failed to respond after receiving IC.

Citations

Citations to this article as recorded by

Therapeutic Drug Monitoring of 5-Fluorouracil in Head and Neck Cancer Patients: An Interventional Pilot Study
P. Sharmila Nirojini, N.K. Bhuvaneshwari, N. Dharsshini, S. Dhivya Bharathi, K. Velavan
Indian Journal of Medical and Paediatric Oncology.2024; 45(02): 134. CrossRef
An open, multicenter, exploratory study of apatinib mesylate maintenance therapy for recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR1800019375)
Jinlong Wei, Jing Su, Jianfeng Wang, Xiaojing Jia, Qin Zhao, Weiyan Shi, Huanhuan Wang, Zhuangzhuang Zheng, Xin Jiang
Head & Neck.2024; 46(4): 915. CrossRef
Current status of systemic therapy in head and neck cancer
Abhenil Mittal, Atul Sharma
Journal of Chemotherapy.2022; 34(1): 9. CrossRef
Risk stratification of postoperative recurrence in hypopharyngeal squamous-cell carcinoma patients with nodal metastasis
Hanqing Lin, Tian Wang, Yu Heng, Xiaoke Zhu, Liang Zhou, Ming Zhang, Yong Shi, Pengyu Cao, Lei Tao
Journal of Cancer Research and Clinical Oncology.2021; 147(3): 803. CrossRef
Clinical characteristics of head and neck cancers at a tertiary care hospital
Sajid Durrani, Saleh Al-Dhahari, Haneen Sebeih, Tariq Wani, Khalid Al Qahatani, Humariya Heena
Population Medicine.2020;[Epub] CrossRef
Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy
Simon Keek, Sebastian Sanduleanu, Frederik Wesseling, Reinout de Roest, Michiel van den Brekel, Martijn van der Heijden, Conchita Vens, Calareso Giuseppina, Lisa Licitra, Kathrin Scheckenbach, Marije Vergeer, C. René Leemans, Ruud H Brakenhoff, Irene Naut
PLOS ONE.2020; 15(5): e0232639. CrossRef
Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience
Or Dagan, Assaf Moore, Yuval Nachalon, Uri Alkan, Ameen Biadsee, Isaac Shochat, Aron Popovtzer
Head & Neck.2020; 42(11): 3118. CrossRef
Meta‐analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck
Kimberley L. Kiong, Nurun Nisa de Souza, Rehena Sultana, N. Gopalakrishna Iyer
The Laryngoscope.2018; 128(7): 1594. CrossRef
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
R.I. Haddad, M. Posner, R. Hitt, E.E.W. Cohen, J. Schulten, J.-L. Lefebvre, J.B. Vermorken
Annals of Oncology.2018; 29(5): 1130. CrossRef
Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief
Andy Karabajakian, Max Gau, Thibault Reverdy, Eve-Marie Neidhardt, Jérôme Fayette
Cancers.2018; 11(1): 15. CrossRef
Revisiting Induction Chemotherapy Before Radiotherapy for Head and Neck Cancer, Part I: Carcinoma of Non-Nasopharyngeal Sites
Christopher H Chapman, Upendra Parvathaneni, Sue S Yom
Future Oncology.2017; 13(6): 469. CrossRef
Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer
Mi Joo Chung, Yeon Sil Kim, Ji Yoon Kim, Yun Hee Lee, Ji Hyun Jang, Jin Hyoung Kang, Ie Ryung Yoo, Youn Soo Lee
Cancer Research and Treatment.2016; 48(4): 1167. CrossRef
The impact of treatment on quality of life of patients with head and neck cancer and its association with prognosis
J.F. Carrillo, L.C. Carrillo, M.C. Ramirez-Ortega, F.J. Ochoa-Carrillo, L.F. Oñate-Ocaña
European Journal of Surgical Oncology (EJSO).2016; 42(10): 1614. CrossRef
Higher positive lymph node ratio indicates poorer distant metastasis–free survival in adenoid cystic carcinoma patients with nodal involvement
Zhonglong Liu, Zao Fang, Tianguo Dai, Chenping Zhang, Jian Sun, Yue He
Journal of Cranio-Maxillofacial Surgery.2015; 43(6): 751. CrossRef

12,977 View
91 Download
13 Web of Science
14 Crossref

Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Importance of Patient Selection for the Postoperative Chemoradiotherapy: Jong Hoon Lee, Jin Ho Song, Sang Nam Lee, Jin Hyoung Kang, Min Sik Kim, Dong Il Sun, Yeon-Sil Kim; Cancer Res Treat. 2013;45(1):31-39. Published online March 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.1.31

Abstract PDF PubReader ePub

PURPOSE
We wanted to evaluate the role of postoperative chemoradiotherapy (CRT) for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
MATERIALS AND METHODS
From March 1993 to July 2008, 101 patients with advanced SCCHN and who had undergone macroscopically complete resection were enrolled. Survival and the cumulative incidence of local or regional relapse, metastasis, and acute toxicity were analyzed.
RESULTS
There was a marginally significant difference of disease-free survival at five years in favor of the CRT arm (51.3% vs. 41.8%, respectively; p=0.10). However, there was no significant difference in overall survival between the two treatment arms (p=0.20). The rate of locoregional failure only for the radiotherapy arm was significantly higher than that for the CRT arm (23.2% vs. 4.4%, respectively; p=0.01). The incidence of grade 3 or 4 hematologic toxicity was significantly higher in the CRT arm than that in the radiotherapy arm (37.7% vs. 1.7%, respectively; p=0.01). In CRT arm, early mortality group within 1 year had low performance status and old age over sixty compared with those of the others.
CONCLUSION
After curative-intent surgery, adjuvant CRT is more effective in locoregional tumor control than radiotherapy alone for patients with advanced SCCHN. However, compared with radiotherapy alone, this combined modality treatment had no survival benefit, and was significantly associated with increased toxicity. Thus, patients with low performance status and old age must be cautious in selection of toxic trimodality treatment.

Citations

Citations to this article as recorded by

Therapeutic Drug Monitoring of 5-Fluorouracil in Head and Neck Cancer Patients: An Interventional Pilot Study
P. Sharmila Nirojini, N.K. Bhuvaneshwari, N. Dharsshini, S. Dhivya Bharathi, K. Velavan
Indian Journal of Medical and Paediatric Oncology.2024; 45(02): 134. CrossRef
Modern management of distant metastases from head and neck squamous cell carcinoma
Patrick Bradley, Claudia Montenegro, Cesare Piazza
Current Opinion in Otolaryngology & Head & Neck Surgery.2024;[Epub] CrossRef
Factors Associated with Patient Survival in Clear Cell Adenocarcinoma of the Cervix: A Single-Center Experience in China
Ting Wang, Zhiying Lu, Xiaodan Zhang, Keqin Hua
International Journal of General Medicine.2022; Volume 15: 4625. CrossRef
Adding Concomitant Chemotherapy to Postoperative Radiotherapy in Oral Cavity Carcinoma with Minor Risk Factors: Systematic Review of the Literature and Meta-Analysis
Alessia Di Rito, Francesco Fiorica, Roberta Carbonara, Francesca Di Pressa, Federica Bertolini, Francesco Mannavola, Frank Lohr, Angela Sardaro, Elisa D’Angelo
Cancers.2022; 14(15): 3704. CrossRef
Metastatic disease in head & neck oncology
Paolo Pisani, Mario Airoldi, Anastasia Allais, Paolo Aluffi Valletti, Mariapina Battista, Marco Benazzo, Roberto Briatore, Salvatore Cacciola, Salvatore Cocuzza, Andrea Colombo, Bice Conti, Alberto Costanzo, Laura della Vecchia, Nerina Denaro, Cesare Fant
Acta Otorhinolaryngologica Italica.2020; 40(SUPPL. 1): S1. CrossRef
The Efficacy of Low Postoperative Radiation Dose in Patients with Advanced Hypopharyngeal Cancer without High-Risk Factors

Hengmin Tao, Zhong Shen, Zhichao Liu, Yumei Wei
Cancer Management and Research.2020; Volume 12: 7553. CrossRef
Contemporary treatment patterns and outcomes of salivary gland carcinoma: a National Cancer Database review
Jay K. Ferrell, Jess C. Mace, Daniel Clayburgh
European Archives of Oto-Rhino-Laryngology.2019; 276(4): 1135. CrossRef
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4
Shinji Yamada, Shunsuke Itai, Mika K. Kaneko, Yukinari Kato
Biochemistry and Biophysics Reports.2018; 13: 123. CrossRef
Postoperative radiotherapy dose requirement in standard combined-modality practice for head and neck squamous cell carcinoma: Analysis of salient surgical and radiotherapy parameters in 2 cohorts
Bidhu K. Mohanti, Alok Thakar, Jaspreet Kaur, Sudhir Bahadur, Monica Malik, Ajeet K. Gandhi, Suman Bhasker, Atul Sharma
Head & Neck.2017; 39(9): 1788. CrossRef
Silencing of FANCD2 enhances the radiosensitivity of metastatic cervical lymph node-derived head and neck squamous cell carcinoma HSC-4 cells
Hua-Jun Feng, Yi-Lin Bao, Zhuo-Ping Liang, Fei-Peng Zhao, Sheng-En Xu, Wei Xu, Chong Zhao, Gang Qin
International Journal of Oncology.2017; 50(4): 1241. CrossRef
Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?
Merdan Fayda, Mustafa Isin, Makbule Tambas, Murat Guveli, Rasim Meral, Musa Altun, Dilek Sahin, Gozde Ozkan, Yasemin Sanli, Husniye Isin, Emre Ozgur, Ugur Gezer
Tumor Biology.2016; 37(3): 3969. CrossRef
Diagnostic and therapeutic features associated with modification of quality-of-life's outcomes between one and six months after major surgery for head and neck cancer
Margherita Gobbo, Federica Bullo, Giuseppe Perinetti, Annalisa Gatto, Giulia Ottaviani, Matteo Biasotto, Giancarlo Tirelli
Brazilian Journal of Otorhinolaryngology.2016; 82(5): 548. CrossRef
Recurrence patterns after postoperative radiotherapy for squamous cell carcinoma of the pharynx and larynx
Yusuke Iizuka, Michio Yoshimura, Haruo Inokuchi, Yukinori Matsuo, Akira Nakamura, Takashi Mizowaki, Shigeru Hirano, Morimasa Kitamura, Ichiro Tateya, Masahiro Hiraoka
Acta Oto-Laryngologica.2015; 135(1): 96. CrossRef
Chemotherapy of Head and Neck Cancer
Chang Ki Yeo
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291. CrossRef
Photochemotherapeutic effects of UV-C on acridine orange in human breast cancer cells: potential application in anticancer therapy
Arunkumar Pitchaimani, Arun Renganathan, Selvamurugan Cinthaikinian, Kumpati Premkumar
RSC Advances.2014; 4(42): 22123. CrossRef
Analysis of the Prognostic Factors for Distant Metastasis after Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Head and Neck Cancer
Dong Hyun Kim, Won Taek Kim, Joo Hye Lee, Yong Kan Ki, Ji Ho Nam, Byung Joo Lee, Jin Choon Lee, Young Jin Choi, Young Mi Seol, Dong Won Kim
Cancer Research and Treatment.1970; 47(1): 46. CrossRef

24,572 View
83 Download
16 Crossref

Clinical Factors Related to Suspected Second Primary Lung Cancer Development in Patients with Head and Neck Cancer: Eui Bae Kim, Yong Park, Seh Jong Park, Dae Sik Kim, Jee Won Kim, Hee Yun Seo, Hwa Jung Sung, In Keun Choi, Kyong Hwa Park, Sang Cheul Oh, Chul Won Choi, Byung Soo Kim, Yeul Hong Kim, Jun Suk Kim, Sang Won Shin, Chul Yong Kim, Kwang-Yoon Jung; Cancer Res Treat. 2008;40(4):178-183. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.178

Abstract PDF PubReader ePub

Purpose

The rate of second primary lung cancer development for patients with head and neck cancer (HNC) has been noted. The aim of our study was to evaluate the incidence and clinical features of suspected second primary lung cancer that developed in patients with primary HNC.

Materials and Methods

We conducted a retrospective study of 469 patients who were newly diagnosed with HNC at the Korea University Medical Center between January 2000 and December 2006.

Results

A total of 469 patients were included (389 men and 80 women). Eighteen patients (3.8%) had suspected second primary lung cancers. Statistically significant clinical variables for lung cancer development included the origin site for the primary HNC (oro-hypopharynx and larynx) (p=0.048), abnormal chest x-ray findings (p=0.027) and the histological HNC type (squamous cell carcinoma) (p=0.032). When the second primary lung cancers were combined with HNCs, the adjusted overall survival of patients with a second primary lung cancer was 16 months (p<0.001).

Conclusions

Considering the relative risk factors for a second primary lung cancer developing in patients with HNC, advanced diagnostic tools, such as chest CT or PET CT scan, should be applied for the early detection of a second primary lung cancer.

Citations

Citations to this article as recorded by

African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer
Yusra F. Shao, Seongho Kim, John D. Cramer, Dina Farhat, Jeffrey Hotaling, Syed Naweed Raza, George Yoo, Ho‐sheng Lin, Harold Kim, Ammar Sukari, Misako Nagasaka
Head & Neck.2022; 44(10): 2069. CrossRef
Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?
Tarun Jain, Guman Singh, Sumit Goyal, Ajay Yadav, Dinesh Yadav, Nitin Khunteta, Hemant Malhotra
World Journal of Nuclear Medicine.2021; 20(02): 164. CrossRef
Modern Radiology in the Management of Head and Neck Cancer
G.J.C. Burkill, R.M. Evans, V.V. Raman, S.E.J. Connor
Clinical Oncology.2016; 28(7): 440. CrossRef
Synchronous Squamous Cell Carcinoma and Chronic Lymphocytic Leukemia of the Palate
Pablo Rosado, Soledad Fernández, Luis Junquera, Juan Carlos De Vicente
Journal of Craniofacial Surgery.2011; 22(1): 348. CrossRef

11,168 View
72 Download
4 Crossref

The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer: Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim, Joon-Kyoo Lee, Deok-Hwan Yang, Yeo-Kyeoung Kim, Je-Jung Lee, Sang-Chul Lim, Hyeoung-Joon Kim, Woong-Ki Chung, Ik-Joo Chung; Cancer Res Treat. 2007;39(3):93-98. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.93

Abstract PDF PubReader ePub

Purpose

This study was performed to determine the feasibility and safety of the use of induction chemotherapy combined with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiation therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Materials and Methods

The patients, that were initially not treated for locally advanced SCCHN, underwent three cycles of induction chemotherapy every 3 weeks at a dose of 70 mg/m² docetaxel D1, 75 mg/m² cisplatin D1, 1000 mg/m² 5-FU D1-4, and subsequently received concurrent chemoradiation therapy.

Results

Forty-nine patients were enrolled in this study and forty-three of the patients completed the treatment. The median duration of follow-up was 18 months (range, 6~39 months). All of the patients had stage III (26.5%) or IV (73.5%) squamous cell carcinoma. After sequential therapy, a complete response and partial response was seen in 28 (65.2%) and 13 (30.2%) patients, respectively. The overall response rate was 95.4%. Overall survival and progression-free survival (PFS) at 2 years were 88.7% and 69.7%, respectively. Grade 3~4 neutropenia occurred in 42.2% of the patients and grade 4 thrombocytopenia in 1 cycle (0.7%). Two patients (4.1%) died during the induction chemotherapy due to pneumonia and a subdural hemorrhage, respectively. The group of patients over 65 years of age showed a significant lower dose intensity than that of patients under 65 years of age, but PFS was not significantly different between two groups (p=0.105).

Conclusion

TPF induction chemotherapy followed by concurrent chemoradiotherapy showed a high level of CR and moderate treatment-induced toxicity. Adequate dose modification in elderly patients should be considered to maintain efficacy and avoid treatment-related toxicity.

Citations

Citations to this article as recorded by

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
Yungan TAO, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Benôit Calderon, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Floria
European Journal of Cancer.2023; 183: 24. CrossRef
Serum Levels of Stromal Cell-Derived Factor-1α and Vascular Endothelial Growth Factor Predict Clinical Outcomes in Head and Neck Squamous Cell Carcinoma Patients Receiving TPF Induction Chemotherapy
Yen-Hao Chen, Chih-Yen Chien, Yu-Ming Wang, Shau-Hsuan Li
Biomedicines.2022; 10(4): 803. CrossRef
Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study
Ching-Yun Hsieh, Ming-Yuh Lein, Shih-Neng Yang, Yao-Ching Wang, Yin-Jun Lin, Chen-Yuan Lin, Chun-Hung Hua, Ming-Hsul Tsai, Ching-Chan Lin
BMC Cancer.2020;[Epub] CrossRef
Neutrophil lymphocyte ratio is an independent prognosticator in patients with locally advanced head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Hsiang-Lan Lai, Yeh Tang, Chih-Yen Chien, Fu-Min Fang, Tai-Lin Huang, Tai-Jan Chiu, Shau-Hsuan Li
Journal of Cancer Research and Practice.2019; 6(4): 170. CrossRef
Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study
Yoshiyuki Tsuchiya, Kentaro Ushijima, Tadahide Noguchi, Naruo Okada, Jun-ichi Hayasaka, Yoshinori Jinbu, Hitoshi Ando, Yoshiyuki Mori, Mikio Kusama, Akio Fujimura
Chronobiology International.2018; 35(2): 289. CrossRef
Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology
D. Alterio, M. Cossu Rocca, W. Russell-Edu, S. Dicuonzo, G. Fanetti, G. Marvaso, L. Preda, S. Zorzi, E. Verri, F. Nole’, B. A. Jereczek-Fossa
Medical Oncology.2017;[Epub] CrossRef
Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma
Kaname Sakuma, Ryuki Tamura, Shintaro Hanyu, Haruka Takahashi, Hideaki Sato, Takahiro Oneyama, Akira Yamaguchi, Akira Tanaka
Molecular and Clinical Oncology.2017;[Epub] CrossRef
Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Shau‐Hsuan Li, Wei‐Che Lin, Tai‐Lin Huang, Chang‐Han Chen, Tai‐Jan Chiu, Fu‐Min Fang, Wan‐Ting Huang, Cheng‐Ming Hsu, Sheng‐Dean Luo, Chi‐Chih Lai, Yan‐Ye Su, Hui‐Ching Chuang, Chih‐Yen Chien
Head & Neck.2016;[Epub] CrossRef
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
Yan-Ye Su, Chih-Yen Chien, Sheng-Dean Luo, Tai-Lin Huang, Wei-Che Lin, Fu-Min Fang, Tai-Jan Chiu, Yen-Hao Chen, Chi-Chih Lai, Cheng-Ming Hsu, Shau-Hsuan Li
World Journal of Surgical Oncology.2016;[Epub] CrossRef
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma
Hironori Cho, Suetaka Nishiike, Yoshifumi Yamamoto, Yukinori Takenaka, Susumu Nakahara, Toshimichi Yasui, Atsushi Hanamoto, Hidenori Inohara
Auris Nasus Larynx.2015; 42(5): 396. CrossRef
Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck
Woo Kyun Bae, Jun Eul Hwang, Hyun Jeong Shim, Sang Hee Cho, Ki Hyeong Lee, Hye Suk Han, Eun-Kee Song, Hwan Jung Yun, In Sung Cho, Joon Kyoo Lee, Sang-Chul Lim, Woong-Ki Chung, Ik-Joo Chung
BMC Cancer.2013;[Epub] CrossRef
Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Importance of Patient Selection for the Postoperative Chemoradiotherapy
Jong Hoon Lee, Jin Ho Song, Sang Nam Lee, Jin Hyoung Kang, Min Sik Kim, Dong Il Sun, Yeon-Sil Kim
Cancer Research and Treatment.2013; 45(1): 31. CrossRef
A case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case
Daisuke Iitaka, Atsushi Shiozaki, Hitoshi Fujiwara, Daisuke Ichikawa, Kazuma Okamoto, Shuhei Komatsu, Yasutoshi Murayama, Hisashi Ikoma, Yoshiaki Kuriu, Masayoshi Nakanishi, Toshiya Ochiai, Yukihito Kokuba, Teruhisa Sonoyama, Eigo Otsuji
Surgery Today.2013; 43(5): 556. CrossRef
Usefulness and Indication of Superselective Intra-arterial Chemotherapy via the Radial Artery for Advanced Head and Neck Cancer^|^mdash;a Indication for Inaccessible to Treatment with Seldingers Method^|^mdash;
Junkichi Yokoyama, Shin Ito, Shinichi Ohba, Mitsuhisa Fujimaki, Katsuhisa Ikeda, Makoto Hanaguri
Nippon Jibiinkoka Gakkai Kaiho.2012; 115(6): 625. CrossRef
Examination on the Effect of Docetaxel Dilution Concentration on the Hypersensitivity Revelation Rate
Tatsuya Hayama, Masatoshi Hayasaka, Mei Onuma, Toshimitsu Nakayama, Sadao Amano, Yoshikazu Yoshida
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences).2012; 38(9): 547. CrossRef
Chemotherapy with Modified Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Metastatic Head and Neck Cancer
Jen-Tsun Lin, Guam-Min Lai, Tung-Hao Chang, Mu-Tai Liu, Chu-Ping Bi, Jer-Wei Wang, Mu-Kuan Chen
Advances in Therapy.2012; 29(1): 71. CrossRef
Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue
Minako Suzuki, Hiroshi Ishikawa, Akira Tanaka, Izumi Mataga
Human Cell.2011; 24(1): 21. CrossRef

11,176 View
66 Download
17 Crossref

Combination Chemotherapy with 5-Fluorouracil and Carboplatin for Advanced Head and Neck Cancer: Eun Kyung Cho, Won Sup Lee, Chul Won Jung, Keun Seok Lee, Won Seog Kim, Ki Hyeong Lee, Dae Seog Heo, Yung Jue Bang, Kwang Hyun Kim, Charn II Park, Noe Kyeong Kim; J Korean Cancer Assoc. 1996;28(1):94-104.

Abstract PDF: Twenty-nine patients with previously untreated, locally advanced head and neck cancer were treated with two or three cycles of combination chemotherapy consisting of 5- fluorouracil infusion and carboplatin, followed by surgery and/or curative radiotherapy. Nine patients with recurrent head and neck cancer were treated with the same combination chemotherapy. The results were as follows; 1) Among 28 evaluable patients, response rate was 71.4%(partial response) after neoadjuvant chemotherapy. Following local modality(surgery and/or radiotherapy), response rate was 79%(complete response 51.4%, and partial response 25%). 2) One year survival rate in neoadjuvant group was 83% and one year progression-free survival rate, 68.8%. The progression-free survival of responders was significantly prolonged in comparison with that of non-responders(p<0.05). 3) In palliative treatment group, one partial response(11%) was observed among nine patients. Median time to progression was 6.8 weeks and median survival was 17.7 weeks; there was no significant difference between responders and non-responders. 4) Nausea and vomiting were frequently observed but easily controlled. Hematologic toxicities-leukopenia and thrombocytopenia were observed but were reversible. In conclusion, combination chemotherapy with carboplatin and 5-FU was effective for locally advanced head and neck cancer in neoadjuvant setting, but it had limited benefits for recurrent diseases. Toxicities were tolerable and neurotoxicity, ototoxicity, and nephrotoxicity were not observed.

3,457 View
25 Download

First
Prev
Page of 1
Next
Last

Search